CA2125279A1 - Methods and compositions for reducing multi-drug resistance - Google Patents

Methods and compositions for reducing multi-drug resistance

Info

Publication number
CA2125279A1
CA2125279A1 CA002125279A CA2125279A CA2125279A1 CA 2125279 A1 CA2125279 A1 CA 2125279A1 CA 002125279 A CA002125279 A CA 002125279A CA 2125279 A CA2125279 A CA 2125279A CA 2125279 A1 CA2125279 A1 CA 2125279A1
Authority
CA
Canada
Prior art keywords
approximately
human
acid
fatty acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002125279A
Other languages
English (en)
French (fr)
Inventor
John Sayler Coon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rush Presbyterian St Lukes Medical Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2125279A1 publication Critical patent/CA2125279A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002125279A 1991-12-10 1992-12-09 Methods and compositions for reducing multi-drug resistance Abandoned CA2125279A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80518691A 1991-12-10 1991-12-10
US805,186 1991-12-10
US98276692A 1992-12-07 1992-12-07
US982,766 1992-12-07
PCT/US1992/010563 WO1993011668A1 (en) 1991-12-10 1992-12-09 Methods and compositions for reducing multi-drug resistance

Publications (1)

Publication Number Publication Date
CA2125279A1 true CA2125279A1 (en) 1993-06-24

Family

ID=27122756

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002125279A Abandoned CA2125279A1 (en) 1991-12-10 1992-12-09 Methods and compositions for reducing multi-drug resistance

Country Status (8)

Country Link
EP (1) EP0616493A4 (ja)
JP (1) JPH07502274A (ja)
CN (1) CN1076358A (ja)
AU (1) AU3243393A (ja)
CA (1) CA2125279A1 (ja)
IL (1) IL104063A0 (ja)
MX (1) MX9207150A (ja)
WO (1) WO1993011668A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
CA2130025A1 (en) * 1993-08-25 1995-02-26 Robert B. Peery Method of treating fungal infections
WO1995031981A2 (en) * 1994-05-19 1995-11-30 Rush-Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
JP2002538224A (ja) * 1999-03-09 2002-11-12 プロタルガ，インコーポレーテッド 脂肪酸−抗癌剤複合体およびこの使用
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4889525A (en) * 1982-08-17 1989-12-26 Adamantech, Inc. Sensitization of hypoxic tumor cells and control of growth thereof
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4563351A (en) * 1983-08-01 1986-01-07 Forsyth Dental Infirmary For Children Self-gelling therapeutic compositions for topical application
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4978622A (en) * 1986-06-23 1990-12-18 Regents Of The University Of California Cytophaga-derived immunopotentiator
JP2558107B2 (ja) * 1986-12-18 1996-11-27 第一製薬株式会社 外用剤
US4863968A (en) * 1987-04-09 1989-09-05 Merrell Dow Pharmaceuticals Inc. Methods of treating gout with chalcone derivatives
US4904697A (en) * 1987-04-09 1990-02-27 Merrell Dow Pharmaceuticals Inc. Controlling the growth of certain tumor tissue with chalcone derivatives
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5108989A (en) * 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair

Also Published As

Publication number Publication date
AU3243393A (en) 1993-07-19
WO1993011668A1 (en) 1993-06-24
EP0616493A1 (en) 1994-09-28
MX9207150A (es) 1993-12-01
EP0616493A4 (en) 1994-11-09
CN1076358A (zh) 1993-09-22
JPH07502274A (ja) 1995-03-09
IL104063A0 (en) 1993-05-13

Similar Documents

Publication Publication Date Title
Mickisch et al. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity
US5776891A (en) Compositions for reducing multidrug resistance
RU2166934C2 (ru) Композиции, включающие биологический агент
JP4157600B2 (ja) 化合物、製剤用組成物及びこれらを含む診断装置とこれらの利用
ES2258566T3 (es) Combinaciones de farmacos (por ejemplo, clorpromacina y pentamidina) para el tratamiento de trastornos neoplasicos.
CA2125279A1 (en) Methods and compositions for reducing multi-drug resistance
CN102292069A (zh) 囊泡制剂
US20060034795A1 (en) Cytostatic drug composition
KR101261672B1 (ko) 오로테이트 유도체를 투여하는 경우의 약물의 조직 수준을 경감시키는 조성물 및 방법
CA2031520A1 (en) Cytochalasin compositions and therapeutic methods
WO2005007101A2 (en) Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
BG106460A (bg) Използване на доцетаксел за лечение на хепатоцелуларен карцином
EP0784430B1 (en) Method for reducing unwanted cellular adhesions
Lo et al. Circumvention of multidrug resistance and reduction of cardiotoxicity of doxorubicin in vivo by coupling it with low density lipoprotein
KR20210107029A (ko) 항암제 운반용 입체복합체
Oldham et al. A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer
CN1168452C (zh) 甲氧基吗啉代阿霉素在制备治疗肝肿瘤的药物方面的应用
Kimoto et al. Antitumor effects of SMANCS on rat mammary tumor induced by 7, 12-dimethylbenz [a] anthracene
CA2306090A1 (en) Delivery vehicles for bioactive agents and uses thereof
CA2250403A1 (en) Treatment of cystic disease with tnf-a
JP2010535702A (ja) 薬剤をオロチン酸誘導体として投与することで薬剤の組織内濃度を下げる組成物及びその方法
Tidefelt et al. Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A
Malviya et al. Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer
US20220080025A1 (en) Vitamin e and cancer therapeutic compositions and methods
Marucci et al. Effect of a xanthine analog on human hepatocellular carcinoma cells (Alexander) in culture and in xenografts in SCID mice

Legal Events

Date Code Title Description
FZDE Discontinued